The GPM core observatory satellite saw the developing tropical cyclone east of Madagascar on January 21, 2016 at 0146 UTC (Jan 20 at 8:46 p.m. EST). GPM is a…
Warmer cloud top temperatures means that convection (rising air that leads to the development of thunderstorms that make up a tropical cyclone) has started to…
New findings expose how mitochondria might instigate lupus-like inflammation.
There are many different ways to make nanomaterials but weaving, the oldest and most enduring method of making fabrics, has not been one of them – until now….
To understand what goes on inside a beehive you can't just study the activity of a single bee. Likewise, to understand the photosynthetic light-harvesting that…
Lead investigator Dr. Guadalupe Sabio explains that the results, described in Nature Communications, not only increase our understanding of the mechanisms used…
In a discovery that may lead to ways to prevent frost on airplane parts, condenser coils, and even windshields, a team of researchers led by Virginia Tech has…
The study led by Professor Jörg Vogel from the Würzburg Institute of Molecular Infection Biology also involved researchers from Leipzig and Cologne. The…
Usually, plants are eaten by animals and humans. With carnivorous plants, however, it's the other way round: They have specialised in animals as an extra…
The contents in our genetic information are actually silent (meaning inactive) and first have to be made to “speak”. Like the read head in a tape recorder, RNA…
The present invention refers to a method and a device for improving a person‘s mobility. It is designed as a mobile, technical platform offering space for one person being moved with power assistance.
In contrast to the already known mobility equipment, the technical basis of the inventive mobility platform consists of “rolling legs“ known as whegs (“wheg“ = wheel-like leg / wheel a leg / wheel-legs). These whegs combine the positive features of wheels and legs. To antagonize disturbing effects of alternation, a force coupled mechanical solution is applied.
According to the International Diabetes Federation (IDF), diabetes affects close to 400 million people worldwide and caused 500 billion Euros in health expenditure in 2013. In preclinical and clinical trials, the NMDA receptor antagonist dextrorphan (DXO) and its prodrug dextromethorphan have been shown to harbor antidiabetic properties (Marquard et al., Nat Med 2015). In addition, DXO was shown to protect mouse and human pancreatic beta cells from cell death during a diabetogenic setting.
DXO is well tolerated and sold as over-the-counter (OTC) medication for more than 50 years. However, adverse events are observed, which are likely caused by the action of DXO on the central nervous system (CNS). Here, the scientists developed DXO-derivatives that do not efficiently pass the blood brain barrier (BBB), and thus should cause fewer adverse effects on the CNS, but maintain their antidiabetic properties. Therefore, the derivatives might maintain the good safety profile and antidiabetic properties of its starting substance dextrorphan, but with fewer adverse effects.
The inventors now aim to demonstrate the expected novel clinical benefit in clinical studies.
“This is a real bombshell in the field of neuroscience,” says Terry Sejnowski, Salk professor and co-senior author of the paper, which was published in eLife….
Rail customers expect to be served by trains that function perfectly from the very first day of service. This is particularly true for the new Intercity…
Intense laser pulses can transform transparent material into a plasma that captures energy of the incoming light very efficiently. Scientists from Berlin and…
The bird, described in the current issue of the journal Avian Research, has been named Himalayan forest thrush Zoothera salimalii. The scientific name honors…
Feedback
